To include your compound in the COVID-19 Resource Center, submit it here.

Research cuts in store

Xenova: Research cuts in store

Even before the tariquidar failure, XEN's was in a precarious financial situation, given that it had £12.9 million ($20.6 million) in cash at March 31 -

Read the full 326 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE